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Background: Despite advances in pharmacologic therapy and devices, patients with 
heart failure (HF) continue to have significant rehospitalization rates and risk prediction 
remains challenging. We sought to explore the value of a multi-biomarker panel [includ-
ing NT-proBNP, high-sensitivity cardiac troponin T (hs-TnT), and ST2] on top of clinical 
assessment for long-term prediction of recurrent hospitalizations in HF.
Methods and results: NT-proBNP, hs-TnT, and ST2 (suppression of tumorigenicity-2) 
levels were measured in 891 consecutive ambulatory HF patients. The independent asso-
ciation between the multi-biomarker panel and recurrent hospitalizations was assessed 
through a multivariable negative binomial regression and expressed as incidence rates 
ratios. McFadden pseudo-R2 and goodness-of-fit measures were also used. The total 
number of unplanned hospitalizations [all-cause, cardiovascular (CV)-, and HF-related] 
were selected as the primary endpoints. At a mean follow-up of 4.2 ± 2.1 years, 1623 
all-cause hospitalizations in 498 patients (55.9%), 710 CV-related hospitalizations in 331 
patients (37.2%), and 444 HF-related hospitalizations in 214 patients (24.1%) were reg-
istered. The crude incidence of all-cause, CV-, and HF-related recurrent hospitalizations 
was significantly higher for patients with the multi-biomarker panel above the cut-point 
(hs-TnT > 14 ng/L, NT-proBNP > 1000 ng/L, and ST2 > 35 ng/mL) (all P < 0.001). 
For all-cause, CV-, and HF-related recurrent hospitalizations, the McFadden R2, Akaike 
information criterion, and Bayesian information criterion supported the superiority of 
incorporating the multi-biomarker panel into a clinical predictive model.
conclusion: A multi-biomarker approach based on NT-proBNP, hs-TnT, and ST2 better 
identifies HF patients at risk for recurrent hospitalizations as compared to approaches 
entailing just one or two of these biomarkers. Elucidation of new biophysiological predic-
tors for recurrent hospitalizations may identify patient profiles for focused intervention.
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inTrODUcTiOn
Despite current treatment with evidence-based drugs and devices, 
patients with heart failure (HF) are frequently admitted to the 
hospital because of symptom exacerbation, and once admitted, 
they are often readmitted. HF is the most common cause of hospi-
talization in patients over age 65, accounting for a total estimated 
cost of $30.7 billion according to 2016 heart disease and stroke 
statistics (1); about two thirds of these costs are attributable to 
HF-related hospitalizations. In patients hospitalized for HF, rates 
of rehospitalization remain as high as 50% within 6 months of 
discharge (2). In ambulatory patients, after diagnosis of HF is 
confirmed, 83% patients are hospitalized at least once and 43% 
are hospitalized at least four times (3). The perspective of pay-
per-performance acts as a catalyst for action to limit recurrent 
HF hospitalizations.
Risk prediction of recurrent hospitalizations has often been 
downplayed, with study endpoints focused on time-to-first event 
analysis (4, 5) and disregarding the impact of recurrent readmis-
sions that frequently occur in HF. Recent initiatives advocate for 
including recurrent hospitalizations for risk stratification (6, 7) 
to convey a more realistic and comprehensive picture of the HF 
continuum. Concerns regarding the need to reduce recurrent 
hospitalizations must focus on the prediction of which patients 
with HF are more likely to be readmitted. Risk stratification may 
be refined by the use of biomarkers for different pathobiological 
pathways that established clinical risk factors fail to unmask.
NT-proBNP is indicative of neurohormonal activation 
and myocardial strain (8), high-sensitivity cardiac troponin T 
(hs-TnT) is a surrogate of myocyte injury (9), and ST2 reflects 
myocardial fibrosis, remodeling, and inflammation (10). These 
markers, either alone or in combination, are independently asso-
ciated in time-to-first event analyses with outcomes in patients 
with HF (11–13). However, the value of a multi-biomarker 
profile to refine the risk of recurrent hospitalizations in HF is ill 
defined. Accordingly, we sought to examine the value of a multi-
biomarker panel including NT-proBNP, hs-TnT, and ST2 on top 
of clinical assessment for long-term prediction of recurrent hos-
pitalizations in HF. The state-of-the-art statistics used, including 
multivariable negative binomial regression (NBreg) models and 
incidence rates ratios (IRRs), foregrounds the impact of recurrent 
hospitalizations.
MaTerials anD MeThODs
study Population
From May 2006 to July 2010, ambulatory patients treated at a 
multidisciplinary HF clinic were consecutively included in the 
study in an outpatient setting. Referral inclusion criteria and 
blood sample collection have been described elsewhere (11, 14). 
In summary, patients were referred to the HF clinic by cardiology 
or internal medicine departments and, to a lesser extent, from the 
emergency or other hospital departments. The principal referral 
criterion was HF according to the European Society of Cardiology 
guidelines irrespective of etiology, at least one hospitalization 
for HF, or a reduced left ventricular ejection fraction (LVEF). 
NT-proBNP, hs-TnT, and ST2 were analyzed from the same blood 
sample stored at −80°, without previous freeze–thaw cycles. All 
samples were obtained between 09:00 a.m. and 12:00 p.m.
All participants provided written informed consent, and the 
local ethics committee approved the study. All study procedures 
were in accord with the ethical standards outlined in the Helsinki 
Declaration of 1975, as revised in 1983.
Follow-up and Outcomes
All patients were followed at regular predefined intervals, with 
additional visits as required in case of decompensation. The 
regular visitation schedule included a minimum of quarterly 
visits with nurses, biannual visits with physicians, and elective 
visits with geriatricians, psychiatrists, and rehabilitation physi-
cians (11, 14). Patients who did not attend the regular visits were 
contacted by telephone.
The total number of unplanned hospitalizations [all-cause, car-
diovascular (CV)-, and HF-related] were selected as the primary 
endpoints. CV admissions were considered as those occurring 
due to acute coronary syndrome, arrhythmias, stroke, or other 
CV causes such as rupture of an aneurysm, peripheral ischemia, 
or aortic dissection. Hospitalizations were identified from clinic 
records of patients in the HF unit and hospital wards and from 
the electronic Catalan history record. Fatal events were identi-
fied from the clinical records from the HF unit, hospital wards, 
emergency room, and general practitioners, and by contacting 
the patient’s relatives. Furthermore, data were verified from the 
databases of the Catalan and Spanish Health Systems. Six patients 
lost during follow-up were adequately censored.
nT-proBnP assay
NT-proBNP levels were determined using an immuno-elec-
trochemiluminescence method (Elecsys®, Roche Diagnostics, 
Switzerland). This assay has <0.001% cross-reactivity with bioac-
tive BNP, and in the constituent studies in this report, the assay 
had inter-run coefficients of variation ranging from 0.9 to 5.5%.
high-sensitivity cardiac Troponin T assay
Troponin levels were measured by electrochemiluminescence 
immunoassay using the hs-TnT assay on the Modular Analytics E 
170 (Roche Diagnostics). The hs-TnT assay has an analytic range 
from 3 to 10,000 ng/L. At the 99th percentile value of 13 ng/L, the 
coefficient of variation was 9%.
sT2 assay
ST2 was measured from plasma samples using a high-sensitivity 
sandwich monoclonal immunoassay (Presage® ST2 assay, Critical 
Diagnostics, San Diego, CA, USA). The ST2 assay had a within-
run coefficient of <2.5%, a total coefficient of variation of 4%, and 
a limit of detection of 1.31 ng/mL.
statistical analysis
Continuous variables were expressed as mean  ±  1 SD or 
median [interquartile range (IQR)] when appropriate. Normal 
TaBle 1 | Demographic and clinical characteristics relative to the number of hF-related hospitalizations.
number of hF-related hospitalizations P value
none (n = 677) One (n = 103) Two (n = 62) Three or more (n = 49)
Age, years 65.2 ± 12.8 71.3 ± 10 70.1 ± 9.9 68.6 ± 9.4 <0.001
Males 501 (74.0) 70 (68.0) 40 (64.5) 27 (55.1) 0.001
White 671 (99.1) 103 (100) 62 (100) 49 (100) 0.25
Etiology
Ischemic heart disease 354 (52.3) 64 (62.1) 31 (50.0) 21 (42.9) 0.89
Dilated cardiomyopathy 64 (9.5) 10 (9.7) 7 (11.3) 5 (10.2) 0.70
Hypertensive 57 (8.4) 8 (7.8) 8 (12.9) 9 (18.4) 0.08
Alcohol 40 (5.9) 3 (2.9) 3 (4.8) 4 (8.2) 0.62
Toxic (drugs) 20 (3.0) 1 (1.0) 1 (1.6) 1 (2.0) 0.24
Valvular 103 (11.2) 12 (11.7) 10 (16.1) 7 (14.3) 0.31
Other 66 (9.7) 5 (4.9) 2 (3.2) 2 (4.1) 0.01
Heart failure duration, months 25.6 (3.7–67.8) 29.2 (11–96) 36 (9.5–92.8) 36 (8.6–95.6) 0.003
LVEF, % 32.8 ± 12.2 34.9 ± 15.6 35.9 ± 16.3 33.9 ± 16.3 0.40
NYHA functional class III–IV 157 (23.2) 42 (40.7) 25 (40.3) 18 (36.7) <0.001
Hypertension 407 (60.1) 67 (65.0) 42 (67.7) 35 (71.4) <0.05
Diabetes mellitus 218 (32.2) 39 (37.9) 32 (51.6) 25 (51.0) <0.001
BMI, kg/m2 26.8 (24–30.4) 26.4 (23.9–31.1) 27.4 (25.5–30.2) 28.3 (25.8–31.8) 0.04
eGFR, mL/min/1.73 m2 56.8 ± 26.9 43.4 ± 24.4 45.7 ± 18.9 43.5 ± 27.6 <0.001
Sodium, mmol/L 139 ± 3.4 139.3 ± 3.5 139 ± 3.2 139.5 ± 3.7 0.14
Hemoglobin, g/dL 13 ± 1.9 12.2 ± 1.9 12.6 ± 1.5 12.5 ± 1.9 <0.001
Treatments, n (%)
ACEI or ARB 630 (93.1) 82 (79.6) 57 (91.9) 45 (91.81) 0.13
Beta-blocker 625 (92.3) 90 (87.4) 51 (82.3) 42 (85.7) 0.004
Spironolactone/eplerenone 368 (54.4) 59 (57.3) 49 (79.0) 37 (75.5) <0.001
Loop diuretic 606 (89.5) 103 (100) 62 (100) 49 (100) <0.001
Digoxin 258 (38.1) 47 (45.6) 40 (64.5) 33 (67.3) <0.001
NT-proBNP, ng/L 1008 (388–2495) 1867 (744–4907) 1721 (938–3512) 1847 (843–3682) <0.001
ST2, ng/mL 37.1 (30.3–49.1) 40.5 (33–53) 44.41 (31.1–65.5) 41.1 (32–58) 0.001
Hs-TnT, ng/L 19 (8.6–36.9) 32.6 (19–52.2) 28.1 (19.1–44.1) 32.5 (19.4–48.8) <0.001
Data are mean ± SD, median (IQR), or n (%).
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; eGRF, estimated glomerular renal filtration (CKD-EPI equation); hs-TnT, 
high-sensitivity troponin T; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; NT-proBNP, N-terminal pro-brain natriuretic peptide; ST2, soluble ST2.
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distribution was assessed by normal Q–Q plots. Discrete vari-
ables were summarized as percentages. Clinical characteristics 
were compared among patients with none, one, two, or three 
or more HF-related hospitalizations and also among biomarker 
strata. P values for trend for continuous variables and for each HF 
etiology were calculated using Spearman correlation. Categorical 
variables were compared using chi-square test (linear by linear).
Biomarker strata relied on categorical use of the three bio-
markers using widely accepted cut-points, namely, 1000  ng/L 
for NT-proBNP, 14 ng/L for hs-TnT, and 35 ng/mL for ST2. Four 
strata, each indicative of the number of biomarkers elevated (0, 
1, 2, and 3) were defined. Crude incidence rates (expressed as 
number of readmissions per 100 person-years) were calculated 
for each biomarker strata and for each readmission endpoint 
(all-cause, CV-, and HF-related). Also event-free curves from 
Cox regression analysis were plotted for the first and second 
CV-related hospital admission relative to biomarker strata.
The independent association between biomarkers and recur-
rent hospitalizations was assessed through a multivariable NBreg 
and expressed as IRR. The category “0” of the variable (none of 
the biomarkers elevated) was used as reference.
In addition to the three studied biomarkers, the covariates 
included in the clinical models were as follows for each endpoint: 
(1) all-cause recurrent hospitalizations – age, NYHA class, time 
since HF diagnosis, diabetes mellitus, peripheral artery disease, 
chronic obstructive pulmonary disease, glomerular filtration 
rate, serum sodium, hemoglobin, and treatment with beta-
blockers; (2) CV-recurrent hospitalizations – age, NYHA class, 
time since HF diagnosis, diabetes mellitus, peripheral artery 
disease, glomerular filtration rate, serum sodium, treatment 
with beta-blockers, ACEI/ARB, and loop diuretics; and (3) 
HF-related recurrent hospitalizations – age, gender, NYHA class, 
time since HF diagnosis, diabetes mellitus, glomerular filtration 
rate, sodium, treatment with beta-blockers, and loop diuretics. 
The decision to include a covariate in each model was mainly 
based on backward stepwise selection with Akaike information 
criterion (AIC) as stopping criterion (P =  0.16) to achieve a 
parsimonious model and prevent model overfitting. During 
this process, the linearity assumption for continuous variables 
was simultaneously tested, and transformed if appropriate, with 
fractional polynomials (15).
The McFadden pseudo-R2 and measures of goodness-of-fit 
such as the AIC and the Bayesian information criterion (BIC) 
were used to compare the performance of each multi-biomarker 
model vs. the clinical model without biomarkers. Given any 
two estimated models, the model with the lower BIC and AIC 
scores was preferred. No statistical tests compare different BIC 
or AIC estimations, and lower values indicate a better model. 
TaBle 2 | Differences among patients based on the number of biomarkers above the cut-point.
number of biomarkers above the cut-point P value
none (n = 129) One (n = 210) Two (n = 256) Three (n = 296)
Age, years 58.7 ± 10.8 62.2 ± 12.8 68.4 ± 11.2 71.1 ± 11.2 <0.001
Males 89 (69.0) 154 (73.3) 179 (69.9) 216 (73.0) 0.61
White 127 (98.4) 209 (99.5) 254 (99.2) 295 (99.7) 0.40
Etiology
Ischemic heart disease 63 (48.8) 105 (50.0) 131 (51.2) 171 (57.8) 0.04
Dilated cardiomyopathy 20 (15.5) 24 (11.4) 23 (9.0) 19 (6.4) 0.003
Hypertensive 13 (10.1) 15 (7.1) 27 (10.5) 27 (9.1) 0.82
Alcohol 11 (8.5) 19 (9.0) 14 (5.5) 6 (2.0) <0.001
Toxic (drugs) 2 (1.6) 8 (3.8) 6 (2.3) 7 (2.4) 0.84
Valvular 6 (4.7) 22 (10.5) 29 (11.3) 48 (16.2) 0.001
Other 14 (10.9) 17 (8.1) 26 (10.2) 18 (6.1) 0.14
Heart failure duration, months 42.2 (16.1–75) 36 (10.6–75.1) 25.4 (3–80.1) 21 (2–61) <0.001
LVEF, % 33.4 ± 11.7 33.8 ± 13.5 33.3 ± 14.2 33.1 ± 12.8 0.53
NYHA functional class III–IV 14 (10.9) 31 (14.8) 74 (28.9) 123 (41.6) <0.001
Hypertension 67 (51.9) 109 (51.9) 168 (65.6) 207 (69.9) <0.001
Diabetes mellitus 31 (24.0) 64 (30.5) 99 (38.7) 120 (40.5) <0.001
BMI, kg/m2 27.7 (25.6–31.6) 28.1 (25–31.4) 26.7 (24.6–30.6) 25.6 (22.9–28.9) <0.001
eGFR, mL/min/1.73 m2 70.1 ± 21.6 62.5 ± 27.3 50.2 ± 24.5 43.3 ± 23.3 <0.001
Sodium, mmol/L 140.2 ± 2.5 139.4 ± 3.3 139.5 ± 3.3 138.4 ± 3.8 <0.001
Hemoglobin, g/dL 13.5 ± 1.6 13.4 ± 1.8 12.8 ± 1.8 12.3 ± 1.8 <0.001
Treatments, n (%)
ACEI or ARB 129 (100) 201 (95.7) 239 (93.4) 245 (82.8) <0.001
Beta-blocker 124 (96.1) 200 (95.2) 224 (87.5) 260 (87.8) <0.001
Spironolactone/eplerenone 58 (45.0) 115 (54.8) 157 (61.3) 183 (61.8) 0.001
Loop diuretic 109 (84.5) 191 (91.0) 242 (94.5) 277 (93.6) 0.002
Digoxin 36 (27.9) 85 (40.5) 115 (44.9) 142 (48.0) <0.001
NT-proBNP, ng/L 281 (138–543) 549 (230–835) 1403 (755–2472) 3190 (1852–3190) <0.001
ST2, ng/mL 27.8 (24.3–31.1) 34.5 (29.5–42.2) 35 (30.4–45.6) 51.7 (42.7–70.7) <0.001
Hs-TnT, ng/L 7.3 (4–9.6) 11.5 (6.5–20.9) 26.4 (16.1–40.9) 38.1 (26.9–60.5) <0.001
Data are mean ± SD, median (IQR), or n (%).
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; eGRF, estimated glomerular renal filtration (CKD-EPI equation); hs-TnT, 
high-sensitivity troponin T; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; NT-proBNP, N-terminal pro-brain natriuretic peptide; ST2, soluble ST2.
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These comparisons were made, in turn, for each recurrent 
hospitalization.
A two-sided P value of <0.05 was considered to be statistically 
significant for all analyses. All analyses were performed using 
Stata 14.1 (StataCorp. 2015, Stata Statistical Software: Release 
14.1 College Station, TX, USA: StataCorp LP) and SPSS 15 (SPSS 
Inc., Chicago, IL, USA).
resUlTs
Patients
From May 2006 to July 2010, a total of 891 consecutive HF 
patients were included in this analysis. Table 1 shows the baseline 
characteristics of the study cohort relative to the occurrence of 
none, one, two, and three or more HF-related hospitalizations. 
The mean age of the total cohort was 66.4 ± 12.4 years, 71.6% 
were male, 52.7% showed ischemic etiology, and 87.5% had 
LVEF below 50%. Most of them were in NYHA class II (65.5%). 
The median concentrations (IQR) for NT-proBNP, hs-TnT, and 
ST2 were 1237  ng/mL (481–2798), 22.4  ng/mL (10.5–40.2), 
and 38.1  ng/mL (30.8–50.9), respectively. The number of HF 
hospitalizations tended to increase with age, HF duration, worse 
NYHA functional class, the presence of diabetes mellitus, renal 
dysfunction, and anemia, and higher biomarker concentrations.
Table  2 summarizes patient characteristics relative to the 
multi-biomarker strata of none elevated or one, two, or three 
biomarkers above the cut-point. As the number of biomarkers 
above the cut-point increased, patients tended to be older, with 
shorter HF duration, worse NYHA functional class, and worse 
biochemistry parameters (estimated glomerular filtration rate, 
sodium, hemoglobin) (Table 2).
Outcomes
At a mean follow-up of 4.2 ± 2.1 years, 399 (44.8%) deaths, 1623 
all-cause hospitalizations in 498 patients (55.9%), 710 CV-related 
hospitalizations in 331 patients (37.2%), and 444 HF-related 
hospitalizations in 214 patients (24.1%) were registered. The 
distribution of patients with one, two, three, four, and five or 
more all-cause, CV-, and HF-related hospitalizations is depicted 
in Figure S1 in Supplementary Material. Crude incidences for 
all-cause, CV-, and HF-related recurrent hospitalizations were 
36, 19, and 12 per 100 person-years, respectively.
Multi-Biomarker Profiling and  
recurrent hospitalizations
For patients with the multi-biomarker panel above the cut-point 
(hs-TnT > 14 ng/L, NT-proBNP > 1000 ng/L, and ST2 > 35 ng/mL), 
TaBle 3 | hospitalization crude incidence rates (per 100 person-years) 
relative to biomarker levels.
Biomarker above cut-point Below cut-point P value
all-cause hospitalizations
hs-TnT 52 16 <0.001
NT-proBNP 52 23 <0.001
ST2 47 24 <0.001
cV-related hospitalizations
hs-TnT 28 7 <0.001
NT-proBNP 30 10 <0.001
ST2 25 13 <0.001
hF-related hospitalizations
hs-TnT 18 4 <0.001
NT-proBNP 19 6 <0.001
ST2 16 8 <0.001
Cut-points: hs-TnT, 14 ng/L; NT-proBNP, 1000 ng/L; ST2, 35 ng/mL.
FigUre 1 | crude incidences (per 100 person-years) of 
hospitalizations relative to the number of elevated biomarkers above 
the predefined cut-points. Crude incidence of all-cause, CV-related, and 
HF-related hospitalizations was very significantly related to the number of 
elevated biomarkers. hs-TnT > 14 ng/L, NTproBNP > 1000 ng/L, and 
ST2 > 35 ng/mL.
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the crude incidences of all-cause, CV-, and HF-related recurrent 
hospitalizations were significantly higher (all P < 0.001; Table 3). 
Relative to the number of elevated biomarkers, a stepwise 
increase in the incidences of all-cause and specific causes of 
recurrent hospitalizations was found when moving from none 
to three biomarkers elevated (all P < 0.001; Figure 1). Indeed, 
the number of HF-related hospitalizations per 100 person-years 
significantly rose from 1 to 31 from none to three biomarkers 
elevated (P < 0.001).
Figure 2A shows event-free curves for first CV-related admis-
sion. Hazard ratios (HRs) based on the number of biomarkers 
elevated (taking 0 as reference) were as follows: one elevated 
biomarker, HR 2.57 (95% CI 1.52–4.34), P < 0.001; two elevated 
biomarkers, HR 4.54 (95% CI 4.74–7.54), P < 0.001; and three 
elevated biomarkers, HR 7.29 (95% CI 4.4–12.1), P  <  0.001. 
Figure  2B shows event-free curves for the second CV-related 
admission, considering from discharge date of the first CV-related 
hospitalization. HRs based on the number of biomarkers elevated 
(taking 0 as reference) were as follows: one elevated biomarker, 
HR 3.42 (95% CI 1.03–11.4), P <  0.05; two elevated biomark-
ers, HR 5.58 (95% CI 1.75–17.9), P = 0.004; and three elevated 
biomarkers, HR 5.16 (95% CI 1.62–16.4), P = 0.006.
After multivariable adjustment, gradients of risk remained 
significant for all endpoints, with the strongest association for 
HF-related hospitalizations. Figure  3 shows the corresponding 
IRRs (95% CIs) for 1, 2, or 3 biomarkers elevated compared to 
none for all-cause, CV-, and HF-related recurrent hospitalizations.
For all-cause, CV-, and HF-related recurrent hospitalizations, 
the McFadden R2 as well as the goodness-of-fit measures AIC and 
BIC supported the value of incorporating the multi-biomarker 
panel with NT-proBNP, hs-TnT, and ST2 into a clinical predictive 
model (Table 4).
Finally, in a sensitivity analysis, we tested the interaction 
between a multimarker risk score (TnThs + NTproBNP + ST-2) 
and eGFR <  60  mL/min/1.73  m2 under the same multivariate 
scenario. This analysis showed a non-significant interaction 
among multimarker score and eGFR, revealing, a non-differential 
prognostic effect of this proposed score across renal function 
strata (omnibus P-value for all-cause and CV-readmission were 
0.381 and 0.112, respectively). Importantly, the multimarker risk 
score was strongly associated with the risk of HF readmissions 
in patients with and without renal dysfunction; however, the 
magnitude of the association was greater in patient without renal 
dysfunction.
DiscUssiOn
Most HF readmissions reflect a rise in cardiac filling pressures, 
yet clinical symptoms have not been sufficiently reliable to detect 
early decompensation or responsive enough to allow timely rein-
tervention to avoid hospitalization (16). Thus, levels of cardiac 
biomarkers have the potential to anticipate risk of recurrent 
hospitalization. Our study shows that multi-biomarker profiling 
with NT-proBNP, hs-TnT, and ST2 permits prediction of recur-
rent hospitalizations above and beyond clinical risk factors.
In 2008, Braunwald (17) classified circulating biomarkers 
into categories based on their pathophysiological effects in HF 
and postulated that multiple biomarkers in combination would 
provide a valuable means of risk stratification. A number of 
multi-biomarker combinations to predict outcomes in chronic 
HF have since been tested. The Penn HF Study included high-
sensitivity C-reactive protein, uric acid and myeloperoxidase, 
B-type natriuretic peptide, soluble fms-like tyrosine kinase 
receptor-1, troponin I, and ST2 (18). Patients in the highest multi-
biomarker tertile had a nearly 14-fold unadjusted risk of death, 
transplant, or ventricular assist device placement compared to the 
lowest tertile. Next, Lupón et al. investigated NT-proBNP, ST2, 
and hs-TnT to determine the relative role of each in all-cause 
mortality (14). Again, all three biomarkers incorporated into a 
clinical model yielded better measures of performance at 1-, 2-, 
and 3-year follow-up. These two studies explored the addition 
of a multi-biomarker panel to predict mortality in addition to 
a clinical score but did not explore admissions or recurrent 
hospitalizations.
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FigUre 3 | incidence rate ratios (irrs) of recurrent hospitalizations 
relative to the number of elevated biomarkers above the 
predefined cut-points. All-cause hospitalizations: one elevated 
biomarker, IRR 2.36 (95% CI 1.62–3.42), P < 0.001; two 
elevated biomarkers, IRR 3.64 (95% CI 2.52–5.26), P < 0.001; 
three elevated biomarkers, IRR 4.87 (95% CI03.38–7.03), P < 0.001. CV-
related hospitalizations: one elevated biomarker, IRR 3.16 (95% CI 1.94–
5.15), P < 0.001; two elevated biomarkers, IRR 5.11 (95% CI 3.17–
8.25), P < 0.001; three elevated biomarkers, IRR 7.94 
(95% CI 4.87–12.95), P < 0.001. HF-related hospitalizations: one elevated 
biomarker, IRR 6.15 (95% CI 2.55–14.80), P < 0.001; two elevated 
biomarkers, IRR 11.37 (95% CI 4.82–26.82), P < 0.001; three 
elevated biomarkers, IRR 18.80 (95% CI 7.88–44.84), P < 0.001.
FigUre 2 | event-free survival curves for cV-related recurrent hospitalizations, relative to the number of elevated biomarkers above the predefined 
cut-points. (a) First CV-related hospitalization. (B) Second CV-related hospitalization (from discharge date of the first CV-related hospitalization). hs-TnT > 14 ng/L, 
NTproBNP > 1000 ng/L, and ST2 > 35 ng/mL.
TaBle 4 | Model performance measures.
clinical  
model
Multi-biomarker  
model
Difference
all-cause readmission
Model’s log-likelihood −1657.01 −1611.83 45.18
McFadden R2 0.08 0.11 0.03
AIC 3338.02 3253.66 84.36
BIC 3395.53 3325.55 69.98a
cV-related readmissions
Model’s log-likelihood −1247.12 −1208.16 38.96
McFadden R2 0.08 0.11 0.03
AIC 2518.24 2446.32 71.92
BIC 2575.75 2518.21 57.54a
hF-related readmission
Model’s log-likelihood −852.02 −819.34 32.68
McFadden R2 0.09 0.12 0.04
AIC 1726.04 1666.68 59.36
BIC 1778.76 1733.78 44.98a
Multi-biomarker model – NT-proBNP, hs-TnT, and ST2 on top of clinical model.
Clinical model – see Section “Materials and Methods” for details.
aDifferences >10 are defined as very strong in favor of the model with lower values.
A recent report characterized measurements of NT-proBNP, 
ST2, GDF-15, and hs-TnT in the cohort from the PROTECT 
(ProBNP Outpatient Tailored Chronic Heart Failure) study (19), 
which accounted for HF admissions as time-to-first event but not 
recurrent hospitalizations. By contrast, in our study, all-cause, 
CV-related, and HF-related recurrent hospitalizations were 
examined. All-cause–related and CV-related recurrent hospitali-
zations were 9-fold and 16-fold higher (in terms of HF-related 
hospitalizations per 100 person-years), respectively, if the three 
biomarkers were elevated. Regarding HF-related recurrent hos-
pitalizations, after a mean 4.2 years of follow-up, the number of 
these hospitalizations per 100 person-years was only one if all 
of the biomarkers were below the cut-point and 31 if the three 
studied biomarkers were elevated.
Identifying the “optimal” panel of biomarkers for assessing 
HF remains a formidable task, given the predictive value of the 
studied biomarkers in the different studies. A large prospective 
multicenter study which includes all the biomarkers to identify 
the best panel is warranted. In the present study, among the multi-
ple biomarkers for HF, natriuretic peptides (neurohormonal acti-
vation and ventricular strain), troponins (myocyte injury), and 
ST2 (fibrosis, ventricular remodeling, and inflammation) were 
chosen because they are currently available, US Food and Drug 
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Administration (FDA) approved, and already acknowledged in 
the American College of Cardiology/American Heart Association 
guidelines because of their strong prognostic potential in chronic 
HF (20). The cut-points used in this study were either approved 
by the FDA (i.e., 35 ng/mL for ST2) (21), identified by a multitude 
of clinical reports (i.e., 1000 ng/L for NT-proBNP) (22, 23), or 
the upper reference limit (99th percentile) was provided by the 
manufacturer (i.e., 14 ng/L for hs-TnT).1
It remains uncertain whether biomarkers can be harnessed as 
a tool to guide HF therapy and subsequently reduce recurrent 
hospitalizations. Biomarkers have potential for therapy guidance 
with ACE inhibitors, ARBs, MRAs, β blockers, and diuretics. 
However, at present, insufficient data exist to support therapy 
titration to target lower NT-proBNP, hs-TnT, and ST2 levels. Only 
natriuretic peptides have been prospectively tested, with conflict-
ing results, in part due to disparities in trial designs. The Guiding 
Evidence-Based Therapy Using Biomarker Intensified Treatment 
in Heart Failure (GUIDE-IT) study is designed to definitively 
assess the effects of a natriuretic peptide–guided strategy in 
patients with systolic HF on clinically relevant endpoints of 
mortality, hospitalization, quality of life, and medical resource 
use (24). Our data support the need for further research aiming to 
evaluate the clinical effect of multi-biomarker-guided strategies.
The limitations of the use of time-to-first event statistical 
approaches for recurrent events are obvious. In chronic diseases 
such as HF, time-to-first event ignores the prognostic impact of 
recurrent hospitalizations, thus providing an incomplete epide-
miological picture of the disease. As demonstrated by Rogers et al. 
(25), the inclusion of recurrent events provides a considerable 
gain in statistical power compared with the time-to-first event 
approach. Yet, the most appropriate statistical method for analysis 
of recurrent events remains controversial (25). The approach we 
followed – an NBreg – not only exploits the Poisson distributional 
assumption of recurrent events but also accounts for interdepend-
ence between recurrent hospitalizations; a further adjustment for 
potential heterogeneity was handled by estimating robust SEs. 
It is unfortunate, however, that the traditional discrimination and 
reclassification indices available in time-to-first event analysis 
have not been developed yet for recurrent event statistics.
Some limitations must be acknowledged with regard to 
the present study. First, whether serial measurements of three 
1 Available from: http://www.canada.com/content/dam/roche_canada/en_ca/
documents/package_inserts/troponint-hs-05092744190-english-v6-can.pdf
biomarkers at predefined time points would have improved risk 
stratification was not incorporated into the design and is beyond 
the scope of the present report (26). Second, the population was a 
general HF population treated at a specific and multidisciplinary 
HF unit in a tertiary care hospital; the criteria for deciding patient 
admission were homogeneous and according to institutional 
guidelines. Third, our cohort was composed mainly of patients 
with HF of ischemic etiology and with reduced ejection fraction. 
As such, these results cannot be extrapolated to a global HF 
population.
cOnclUsiOn
Our findings support the value of a multi-biomarker approach 
that incorporates NT-proBNP, hs-TnT, and ST2 to predict the 
risk of recurrent hospitalizations for worsening HF as well as for 
CV-related and all causes. Elucidation of new biophysiological 
predictors for recurrent hospitalizations may be most useful to 
reveal patient profiles for focused intervention.
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